Julien Meissonnier
Chief Tech/Sci/R&D Officer bei CATALENT, INC.
Profil
Julien Meissonnier ist Gründer von Accellix, Inc. und bekleidet derzeit die Position des President & Director bei Accellix, Inc. und Chief Scientific Officer & Vice President bei Catalent, Inc. und Chief Scientific Officer bei Catalent Pharma Solutions, Inc. (eine Tochtergesellschaft von Catalent, Inc.). Zuvor war er President & Chief Executive Officer von Cardio Ventures Ltd., Manager-Business Development bei Sol-Gel Technologies Ltd., Director-Marketing & Business Development bei Evogene Ltd., Manager-Global Marketing bei Novartis AG und Manager-Global Marketing bei Ciba-Geigy AG (eine Tochtergesellschaft der Novartis AG) sowie Entwicklungsingenieur bei Rhone-Poulenc SA. Er erhielt einen Hochschulabschluss von der University of Washington und einen MBA von INSEAD.
Aktive Positionen von Julien Meissonnier
| Unternehmen | Position | Beginn |
|---|---|---|
| CATALENT, INC. | Chief Tech/Sci/R&D Officer | 19.11.2019 |
Accellix, Inc.
 Accellix, Inc. Medical SpecialtiesHealth Technology Accellix, Inc. develops in-vitro diagnostic systems. Its Accellix platform is an affordable tabletop diagnostic device with single-use assay cartridges that does not require extensive training nor involve complex operational processes. The firm’s product is an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test. The company was founded in 2009 by Julien Meissonnier and Harvey Kasdan and is headquartered in San Jose, CA. | Founder | 01.01.2009 |
Catalent Pharma Solutions, Inc.
 Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Chief Tech/Sci/R&D Officer | 01.10.2019 |
Ehemalige bekannte Positionen von Julien Meissonnier
| Unternehmen | Position | Ende |
|---|---|---|
Cardio Ventures Ltd.
 Cardio Ventures Ltd. Investment ManagersFinance Cardio Ventures Ltd is a venture capital firm. The firm headquartered in Jerusalem, Israel. | Chief Executive Officer | 01.01.2011 |
| SOL-GEL TECHNOLOGIES LTD. | Corporate Officer/Principal | - |
| NOVARTIS AG | Sales & Marketing | - |
Ciba-Geigy AG
 Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Sales & Marketing | - |
| EVOGENE LTD. | Sales & Marketing | - |
Ausbildung von Julien Meissonnier
| University of Washington | Graduate Degree |
| INSEAD | Masters Business Admin |
| École Nationale Supérieure d'Ingénieurs de Caen | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| NOVARTIS AG | Health Technology |
| SOL-GEL TECHNOLOGIES LTD. | Health Technology |
| EVOGENE LTD. | Health Technology |
| CATALENT, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Accellix, Inc.
Accellix, Inc. Medical SpecialtiesHealth Technology Accellix, Inc. develops in-vitro diagnostic systems. Its Accellix platform is an affordable tabletop diagnostic device with single-use assay cartridges that does not require extensive training nor involve complex operational processes. The firm’s product is an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test. The company was founded in 2009 by Julien Meissonnier and Harvey Kasdan and is headquartered in San Jose, CA. | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
| Rhone-Poulenc SA | Process Industries |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
Cardio Ventures Ltd.
Cardio Ventures Ltd. Investment ManagersFinance Cardio Ventures Ltd is a venture capital firm. The firm headquartered in Jerusalem, Israel. | Finance |
